Narcolepsy — Research Summary
Printed from RareWays (rareways.com.au) on 10 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Central hypocretin/orexin administration alleviates sleep/wake disturbances, anhedonia, and neuroinflammation in an animal model of seasonal affective disorder.
Costello Allison et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41508567/
- 2.
An updated systematic review and meta-analysis of modafinil for excessive daytime sleepiness in narcolepsy.
Mann Govind Singh et al. — Sleep medicine: X (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41852498/
- 3.
Design, synthesis, and biological evaluation of novel diphenylmethyl-sulfinyl-bridged bisamides as wakefulness-promoting and anti-fatigue agents.
Xiong Haoxin et al. — European journal of medicinal chemistry (5 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42033992/
- 4.
Identification and quantification of Hypocretin-1/Orexin-A 1-14 and 1-16 fragments in immunopurified cerebrospinal fluid using LC-MS: Comparison with radioimmunoassay (RIA) determinations.
Maus Anthony et al. — Sleep medicine (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42127723/
- 5.
Assessment of readiness in the diagnosis and management of central disorders of hypersomnolence: A survey of sleep medicine program directors and fellowship graduates.
Kutscher Scott et al. — Sleep medicine (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42176391/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
Recruiting — Phase 2 — Takeda
https://clinicaltrials.gov/study/NCT07633301
- 2.
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Recruiting — Phase 3 — Alkermes, Inc.
https://clinicaltrials.gov/study/NCT07455383
- 3.
A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia
Recruiting — Na — University of Sydney
https://clinicaltrials.gov/study/NCT07006233
- 4.
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Recruiting — Phase 2 — Alkermes, Inc.
https://clinicaltrials.gov/study/NCT06767683
- 5.
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Recruiting — Phase 2 — Takeda
https://clinicaltrials.gov/study/NCT05816382
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Narcolepsy
Narcolepsy is a chronic neurological condition caused by loss of orexin-producing neurons in the brain, causing excessive daytime sleepiness and cataplexy (sudden muscle weakness triggered by emotion). It is significantly underdiagnosed. Medications can manage symptoms effectively, and orexin-based treatments are in development.
Most Recent Research
BACKGROUND: Seasonal affective disorder (SAD) is a major depressive disorder recurring in fall and winter due to daytime light deficiency. To investigate underlying mechanisms of SAD, we previously developed a diurnal model using Nile grass rats (Arvicanthis niloticus), in which a winter-like dim daylight condition (dimLD) increased depression-like behaviors and neuroinflammation, while attenuating central orexinergic activity compared to grass rats housed in a summer-like bright daylight condition (brLD). MATERIALS AND METHODS: The present study tested the hypothesis that the behavioral and neuroinflammatory responses induced by the winter-like dimLD condition are due to attenuated central orexinergic output. Male and female grass rats housed in dimLD or brLD received intracerebroventricular orexin A (OXA) or vehicle (aCSF) 6 h every morning for one week while sleep/wakefulness were continuously monitored. A saccharin-solution preference test was performed on the last infusion day to assess anhedonia, followed by brain collection for analyzing neuroinflammatory markers in the medial prefrontal cortex, dorsal hippocampus, and basolateral amygdala. RESULTS: OXA treatment promoted daytime wakefulness in females, improved nighttime sleep quality in males, and reduced anhedonia in both sexes of dimLD animals to levels comparable to brLD-aCSF controls. Additionally, treating dimLD animals with OXA increased expression of anti-inflammatory cytokines IL-4 and IL-10, and reduced pro-inflammatory markers including IL-6, CD11b, and the number and inflammatory morphology of microgliadepending on sex and brain site. CONCLUSIONS: These findings support the hypothesis that the orexinergic system mediates the effects of ambient light on sleep and affect, and may be a potential therapeutic target in SAD.
Common Questions
What is Narcolepsy?
Narcolepsy is a chronic neurological condition caused by loss of orexin-producing neurons in the brain, causing excessive daytime sleepiness and cataplexy (sudden muscle weakness triggered by emotion). It is significantly underdiagnosed. Medications can manage symptoms effectively, and orexin-based treatments are in development.
How many clinical trials are available for Narcolepsy?
RareWays currently indexes 147 clinical trials for Narcolepsy, of which 36 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Narcolepsy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Narcolepsy.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.